A ruling in New Jersey
After a two-day hearing in late August, Judge Zahid Quraishi concluded that Novo Nordisk did not deserve a preliminary injunction. In his 25-page decision, he found Novo's argument of irreparable harm unconvincing.
“…inadequate to warrant the extraordinary relief it seeks.” — Zahid Quraishi
The judge found Novo's witnesses credible but noted that Lilly's ads had at most a negligible market impact between April and July, with prescriptions for Novo's products remaining stable. He also said that money damages could compensate Novo for any significant harm without the need for an injunction.
A dispute over weight-loss figures
Novo Nordisk sued Eli Lilly in July, saying the ads violated federal and state false advertising and unfair competition laws. The heart of the dispute includes:
- Ads for Lilly's obesity drug Zepbound and diabetes treatment Mounjaro compared higher doses of those products with lower doses of Novo's Wegovy and Ozempic.
- One commercial claimed that people using Zepbound lost on average about 23 kg (50 pounds), while people using Wegovy lost on average about 15 kg (33 pounds), with a written disclaimer.
















